Discontinued
Antibody (Suitable for clinical applications)
Sample Type: FFPE Patient Samples.
Tested Applications: IHC. Approved for In Vitro Diagnostic Procedures on FFPE tissues. For tissue collection recommendations, please see datasheet sent with product.
Application Notes
Prior to use, inspect vial for the presence of any precipitate or other unusual physical properties. These can indicate that the antibody has degraded and is no longer suitable for patient samples. Please run positive and negative controls simultaneously with all patient samples to account and control for errors in laboratory procedure. Use of methods or materials not recommended by enQuire Bio including change to dilution range and detection system should be routinely validated by the user.
| Specification | Recommendation |
|---|---|
| Recommended Dilution (Conc) | 1:50-1:100 |
| Pretreatment | EDTABuffer pH 8.0 |
| Incubation Parameters | 30 min at Room Temperature |
Clonality: Monoclonal
Anti-CD105 Antibody Clone: EP274
Host and Isotype: Rabbit IgG
Recommended Positive Control Sample: Skin angiosarcoma
Cellular Localization of Antibody EP274 Staining: Cytoplasmic
Buffer and Stabilizer: PBS with 1% BSA and 0.05% NaN3
Antibody Concentration: Lot specific. Plese contact tech support for data.
Immunogen: A protein fragment corresponding to residues on human CD105 protein.
Storage Conditions: This antibody should be stored refrigerated (2-8°C). This product should not be used past the expiration date printed on the vial.
CD105 Information for Pathologists
Summary:
Also called endoglin. CD105 is a regulatory component of the TGF-beta receptor complex. Mutations in CD105 cause Hereditary Hemorrhagic Telangiectasia type I (Am J Hum Genet 1997;61:68). It is required for hemangioblast and early hematopoietic development (Development 2007;134:3041)Common Uses By Pathologists:
Specific and sensitive marker for tumor angiogenesis (better than CD31). Increased microvessel staining is also a prognostic factor for Acute lymphoblastic leukemia in children (Leuk Res 2007;31:1741) Breast carcinoma (Am J Clin Pathol 2003;119:374, including node negative, Hum Pathol 2004;35:176) Chronic idiopathic myelofibrosis (Mod Pathol 2004;17:1513) Colorectal carcinoma (Mod Pathol 2004;17:197) Endometrial carcinoma (Gynecol Oncol 2006;103:1007) Esophageal adenocarcinoma (Hum Pathol 2006;37:861) Gastric carcinoma (Hum Pathol 2006;37:861) Hepatocellular carcinoma (BMC Cancer 2006;6:110) Meningioma (Acta Neuropathol 2007;114:147) Ovarian carcinoma (Int J Gynecol Cancer 2006;16:1789) Primary CNS lymphoma (J Neurooncol 2007;82:249) Prostate adenocarcinoma (Am J Clin Pathol 2007;127:572) and Squamous cell carcinoma of head and neck (Virchows Arch 2006;448:768), including tongue (Laryngoscope 2006;116:1175). Serum CD105 is associated with intrauterine growth restriction during pregnancy (J Clin Endocrinol Metab 2007;92:2831), preeclampsia (N Engl J Med 2006;355:992, Nat Med 2006;12:642), diabetic retinopathy (J Cell Mol Med 2005;9:692). Tissue CD105 is associated with progressive hepatic fibrosis in chronic HCV infection.Limitations and Warranty
This antibody is manufactured in accordance with clinical good manufacturing practices in an ISO13485:2016 certified production facility. It is intended for multiple uses including in vitro diagnostic use and research use only applications. Please see vial label for expiration date. We strive to always deliver antibodies with a shelf life of at least two years.
There are no reviews yet.